Results 241 to 250 of about 255,512 (289)

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials [PDF]

, 2017
et al,, Mutch, David G
core   +1 more source

Chemically Engineered L. reuteri Delivering αPD‐L1 and Gallium Ions via Metal‐Phenolic Networks Potentiate Anti‐Tumor Immunity and Ferroptosis

Advanced Science, EarlyView.
A multifaceted chemical strategy, integrating bacterial tropism, metal‐ion interference therapy, and immunotherapy, resulted in significant tumor regression in murine models. A pioneering paradigm for the design of biohybrid materials was established, highlighting how sophisticated chemical engineering of living systems can unlock new avenues for ...
Tingting Zhang, Mengyi Xu, Yan Zhang, Zhiwen Li, Danqing Song, Jing Pang, Ke Li, Yanxiang Wang   +7 more
wiley   +1 more source

Multigland dysfunction from immune-checkpoint inhibitors: a case of hypothyroidism, diabetes, and adrenal insufficiency. [PDF]

JCEM Case Rep
Vengilote R, Onwudiwe O, Yousef A, Quartuccio M.   +3 more
europepmc   +1 more source

Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects

Advanced Science, EarlyView.
Bacterial outer membrane vesicles (OMVs) have emerged as versatile platforms for cancer vaccine development owing to their intrinsic immunostimulatory properties and high engineering flexibility. This review summarizes OMV biology, immune mechanisms, and engineering strategies that enhance vaccine efficacy, discusses key translational challenges, and ...
Jiabeini Zhang, Tianyu Shao, Fengjiang Qu, Caiyun Bai, Sijie Li, Pin Gao, Wenna Li, Keman Cheng, Xiao Zhao, Zhimin Fan   +9 more
wiley   +1 more source

Intestinal Stenosis Related to Immune Checkpoint Inhibitors Caused by Sintilimab: A Case Report. [PDF]

J Inflamm Res
Li HY, Liu Y, Hu SL, Li YQ, Tang TY.
europepmc   +1 more source

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

Advanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin, Dingqin Cai, Chunli Jian, Yaxian Qi, Linpeng Zheng, Qiao Yang, Longyao Zhang, Diangang Chen, Lingchen Li, Ping Cai, Lingyou Sun, Luping Zhang, Jianguo Sun   +12 more
wiley   +1 more source

Highly activated CD4+ T regulatory cells associated with non- responders to immune-checkpoint inhibitors in metastatic melanoma

Milodowski E, Ball J, Herbert C, Hadi A, Russell L, Addeo A, Winter H, Bartoli-Leonard F, Wooldridge L.   +8 more
europepmc   +1 more source

Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world study. [PDF]

Oncologist
Kong H, Chen Y, Li H, Wang D, Chang X, Zeng Z, Zhang W.   +6 more
europepmc   +1 more source

Onset and Outcomes of Immune-related Adverse Events in Genitourinary Cancer Treated With Immune Checkpoint Inhibitors. [PDF]

In Vivo
Kato M, Yamamoto S, Matsue T, Yukimatsu N, Otoshi T, Yamasaki T, Kaneda H, Kurajoh M, Ito A, Odagiri N, Nakata A, Kobayashi A, Kuratsukuri K, Uchida J.   +13 more
europepmc   +1 more source

Prognostic value of the C-PLAN index in patients with advanced esophageal cancer treated with immune checkpoint inhibitors. [PDF]

Clinics (Sao Paulo)
Shao S, Zhang H, Gu Y, Yang X, Huang J.
europepmc   +1 more source